keyword
MENU ▼
Read by QxMD icon Read
search

Nicolaus Kröger

keyword
https://read.qxmd.com/read/30760453/comprehensive-clinical-molecular-transplant-scoring-system-for-myelofibrosis-undergoing-stem-cell-transplantation
#1
Nico Gagelmann, Markus Ditschkowski, Rashit Bogdanov, Swan Bredin, Marie Robin, Bruno Cassinat, Rabia Shahswar, Felicitas Thol, Michael Heuser, Gerard Socié, Dietrich Beelen, Ioanna Triviai, Anita Badbaran, Nicolaus Kröger
Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantation itself using clinical, molecular and transplant-specific information of a total of 361 myelofibrosis patients. Of these, 205 patients were used as a training cohort to create a clinical-molecular myelofibrosis transplant scoring system (MTSS), which was then externally validated in a cohort of 156 patients...
February 13, 2019: Blood
https://read.qxmd.com/read/30733269/long-term-outcome-after-allogeneic-hematopoietic-cell-transplantation-for-myelofibrosis
#2
Marie Robin, Liesbeth C de Wreede, Christine Wolschke, Johannes Schetelig, Dirk-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Aleksandar Radujkovic, Donal McLornan, Yves Chalandon, Nicolaus Kröger
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated...
February 7, 2019: Haematologica
https://read.qxmd.com/read/30709437/acute-gvhd-prophylaxis-plus-atlg-after-myeloablative-allogeneic-haemopoietic-peripheral-blood-stem-cell-transplantation-from-hla-identical-siblings-in-patients-with-acute-myeloid-leukaemia-in-remission-final-results-of-quality-of-life-and-long-term-outcome
#3
RANDOMIZED CONTROLLED TRIAL
Francesca Bonifazi, Carlos Solano, Christine Wolschke, Mariarosaria Sessa, Francesca Patriarca, Francesco Zallio, Arnon Nagler, Carmine Selleri, Antonio Maria Risitano, Giuseppe Messina, Wolfgang Bethge, Pilar Herrera, Anna Sureda, Angelo Michele Carella, Michele Cimminiello, Stefano Guidi, Jürgen Finke, Roberto Sorasio, Christelle Ferra, Jorge Sierra, Domenico Russo, Edoardo Benedetti, Giuseppe Milone, Fabio Benedetti, Marion Heinzelmann, Domenico Pastore, Manuel Jurado, Elisabetta Terruzzi, Franco Narni, Andreas Völp, Francis Ayuk, Tapani Ruutu, Nicolaus Kröger
BACKGROUND: We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS)...
February 2019: Lancet Haematology
https://read.qxmd.com/read/30658222/biology-driven-approaches-to-prevent-and-treat-relapse-of-myeloid-neoplasia-after-allogeneic-hematopoietic-stem-cell-transplantation
#4
REVIEW
Robert Zeiser, Dietrich W Beelen, Wolfgang Bethge, Martin Bornhäuser, Gesine Bug, Andreas Burchert, Maximilian Christopeit, Justus Duyster, Jürgen Finke, Armin Gerbitz, Jan Henning Klusmann, Guido Kobbe, Michael Lübbert, Carsten Müller-Tidow, Uwe Platzbecker, Wolf Rösler, Martin Sauer, Christoph Schmid, Thomas Schroeder, Mathias Stelljes, Nicolaus Kröger, Lutz P Müller
The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) mainly relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview on the established and evolving approaches to prevent or treat relapse of AML and MDS after allo-HCT, in the context of novels insight into the biology of relapse...
January 15, 2019: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30655377/optimized-ebmt-transplant-specific-risk-score-in-myelodysplastic-syndromes-after-allogeneic-stem-cell-transplantation
#5
Nico Gagelmann, Diderik-Jan Eikema, Matthias Stelljes, Dietrich Beelen, Liesbeth de Wreede, Ghulam Mufti, Nina Simone Knelange, Dietger Niederwieser, Lone S Friis, Gerhard Ehnninger, Arnon Nagler, Ibrahim Yakoub-Agha, Ellen Meijer, Per Ljungman, Johan Maertens, Lothar Kanz, Lucia Lopez-Corral, Arne Brecht, Charles Craddock, Jürgen Finke, Jan J Cornelissen, Paolo Bernasconi, Patrice Chevallier, Jorge Sierra, Marie Robin, Nicolaus Kröger
Here, we aimed to develop and validate a clinical and transplant-specific prognostic score in a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was assessed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky performance status < 90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 x 109/L prior to transplantation...
January 17, 2019: Haematologica
https://read.qxmd.com/read/30655365/antilymphocyte-globulin-for-matched-sibling-donor-transplantation-in-patients-with-myelofibrosis
#6
Marie Robin, Sylvie Chevret, Linda Koster, Christine Wolschke, Ibrahim Yakoub-Agha, Jean-Henri Bourhis, Patrice Chevallier, Jan J Cornelissen, Péter Reményi, Johan Maertens, Xavier Poiré, Charles Craddock, Gérard Socié, Maija Itälä-Remes, Harry C Schouten, Tony Marchand, Jakob Passweg, Didier Blaise, Gandhi Damaj, Zubeyde Nur Ozkurt, Tsila Zuckerman, Thomas Cluzeau, Hélène Labussière-Wallet, Jörg Cammenga, Donal McLornan, Yves Chalandon, Nicolaus Kröger
Antihuman T-lymphocyte immunoglobulin is still much debated in the setting of transplant from an HLA matched related donor. Acute and chronic graft-versus-host disease are the main cause of morbidity and mortality after allogeneic hematopoietic stem cell in patients with myelofibrosis. The aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large cohort of patients with myelofibrosis. 287 patients were included in the study. Cumulative incidence of grade 2-4 acute graft-versus-host disease was 26% and 41% with or without antihuman T-lymphocyte immunoglobulin...
January 17, 2019: Haematologica
https://read.qxmd.com/read/30573777/late-treatment-related-mortality-versus-competing-causes-of-death-after-allogeneic-transplantation-for-myelodysplastic-syndromes-and-secondary-acute-myeloid-leukemia
#7
Johannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, Linda Koster, Jürgen Finke, Dietger Niederwieser, Dietrich Beelen, G J Mufti, Uwe Platzbecker, Arnold Ganser, Silke Heidenreich, Johan Maertens, Gerard Socié, Arne Brecht, Matthias Stelljes, Guido Kobbe, Liisa Volin, Arnon Nagler, Antonin Vitek, Thomas Luft, Per Ljungman, Ibrahim Yakoub-Agha, Marie Robin, Nicolaus Kröger
The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT on 6434 adults, who received a first alloHCT from January 2000 to December 2012, were retrospectively studied using combined land-marking, relative-survival methods and multi-state modeling techniques. Median age at alloHCT increased from 49 to 58 years, and the number of patients aged ≥65 years at alloHCT increased from 5 to 17%...
December 20, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://read.qxmd.com/read/30408564/family-mismatched-allogeneic-stem-cell-transplantation-for-myelofibrosis-report-from-the-chronic-malignancies-working-party-of-european-society-for-blood-and-marrow-transplantation
#8
Kavita Raj, Diderik-Jan Eikema, Donal P McLornan, Eduardo Olavarria, Henric-Jan Blok, Stefania Bregante, Fabio Ciceri, Jakob Passweg, Per Ljungman, Nicolaas Schaap, Kristina Carlson, Tsila Zuckerman, Liesbeth C de Wreede, Liisa Volin, Yener Koc, Jose Luis Diez-Martin, Peter Brossart, Dominik Wolf, Didier Blaise, Paolo Di Bartolomeo, Antonin Vitek, Marie Robin, Ibrahim Yakoub-Agha, Yves Chalandon, Nicolaus Kroger
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106 /kg (range, 1.7 to 22...
November 5, 2018: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30372796/trends-in-patient-outcome-over-the-past-two-decades-following-allogeneic-stem-cell-transplantation-for-acute-myeloid-leukaemia-an-alwp-ebmt-analysis
#9
J Canaani, E Beohou, M Labopin, A Ghavamzadeh, D Beelen, R-M Hamladji, D Niederwieser, L Volin, M Markiewicz, R Arnold, G Mufti, G Ehninger, G Socié, N Kröger, M Mohty, A Nagler
BACKGROUND: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES: To assess the incremental improvement of transplanted AML patients in the last two decades. METHODS: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission...
October 29, 2018: Journal of Internal Medicine
https://read.qxmd.com/read/30361416/haploidentical-versus-unrelated-allogeneic-stem-cell-transplantation-for-relapsed-refractory-acute-myeloid-leukemia-a-report-of-1578-patients-from-the-acute-leukemia-working-party-of-ebmt
#10
Eolia Brissot, Myriam Labopin, Gerhard Ehninger, Matthias Stelljes, Arne Brecht, Arnold Ganser, Johanna Tischer, Nicolaus Kröger, Boris Afanasyev, Jürgen Finke, Ahmet Elmaagacli, Hermann Einsele, Mohamad Mohty, Arnon Nagler
Primary refractory or relapsed acute myeloid leukemia is associated with dismal prognosis. Allogeneic stem cell transplantation is the only therapeutic option that offers prolonged survival and cure in this setting. In the absence of a matched sibling donor, transplantation from unrelated 10/10 or 9/10 and haploidentical donors are potential alternatives. The current study aimed to compare the outcomes of acute myeloid leukemia patients with active disease who received allogeneic stem cell transplantation from a haploidentical donor with post-transplant cyclophosphamide (n=199) versus an unrelated donor 10/10 (n=1111) and versus unrelated donor 9/10 (n=383) between 2007 and 2014 and reported to the EBMT registry...
October 25, 2018: Haematologica
https://read.qxmd.com/read/30317227/return-to-work-in-patients-with-hematological-cancers-1-year-after-treatment-a-prospective-longitudinal-study
#11
Tim J Hartung, Leon P Sautier, Angela Scherwath, Kirsten Sturm, Nicolaus Kröger, Uwe Koch, Anja Mehnert
BACKGROUND: Although hematological cancer survivors have a high risk of disability, data on work-related issues are scarce for this population. METHODS: We investigated return to work (RTW) and work ability (Work Ability Index, WAI) in hematological cancer patients 6 months and 1 year after cancer treatment. We explored associations between baseline sociodemographic and medical characteristics and RTW as well as work ability at follow-up. RESULTS: The participation rate was 42% (baseline n = 91, after 12 months n = 40 (44%))...
2018: Oncology Research and Treatment
https://read.qxmd.com/read/30243581/outcomes-of-haploidentical-transplantation-in-patients-with-relapsed-multiple-myeloma-an-ebmt-cibmtr-report
#12
Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F Dávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Mareike Verbeek, Wolf Rösler, Jose L Diez-Martin, Stefan Schoenland, Anita D'Souza, Nicolaus Kröger, Parameswaran Hari
Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within European Society for Blood and Marrow Transplantation/Center for International Blood and Marrow Transplant Research centers...
September 20, 2018: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30172776/hla-mismatched-donors-in-patients-with-myelodysplastic-syndrome-an-ebmt-registry-analysis
#13
Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise, Christine Wolschke, Linda Koster, Emanuele Angelucci, Friedrich Stölzel, Victoria Potter, Ibrahim Yakoub-Agha, Yener Koc, Fabio Ciceri, Jürgen Finke, Hélène Labussière-Wallet, Maria Jesús Pascual Cascon, Mareike Verbeek, Alessandro Rambaldi, Jan J Cornelissen, Patrice Chevallier, Rohini Radia, Arnon Nagler, Nathalie Fegueux, Eliane Gluckman, Theo de Witte, Nicolaus Kröger
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been reported to give very encouraging results in patients with hematological malignancies. Patients who have no HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood (CB) donor, and a haploidentical related donor. The aim of our study is to compare the outcome of patients with myelodysplastic syndrome (MDS) who have been transplanted from a haploidentical donor using PTCy, an HLA-mismatched unrelated donor (marrow or peripheral blood stem cells), or an unrelated mismatched CB donor...
January 2019: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/30135313/an-early-biomarker-algorithm-predicts-lethal-graft-versus-host-disease-and-survival
#14
Matthew J Hartwell, Umut Özbek, Ernst Holler, Anne S Renteria, Hannah Major-Monfried, Pavan Reddy, Mina Aziz, William J Hogan, Francis Ayuk, Yvonne A Efebera, Elizabeth O Hexner, Udomsak Bunworasate, Muna Qayed, Rainer Ordemann, Matthias Wölfl, Stephan Mielke, Attaphol Pawarode, Yi-Bin Chen, Steven Devine, Andrew C Harris, Madan Jagasia, Carrie L Kitko, Mark R Litzow, Nicolaus Kröger, Franco Locatelli, George Morales, Ryotaro Nakamura, Ran Reshef, Wolf Rösler, Daniela Weber, Kitsada Wudhikarn, Gregory A Yanik, John E Levine, James Lm Ferrara
No abstract text is available yet for this article.
August 23, 2018: JCI Insight
https://read.qxmd.com/read/30116018/methods-and-role-of-minimal-residual-disease-after-stem-cell-transplantation
#15
Marco Ladetto, Sebastian Böttcher, Nicolaus Kröger, Michael A Pulsipher, Peter Bader
Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome...
August 16, 2018: Bone Marrow Transplantation
https://read.qxmd.com/read/30082852/narrowing-the-gap-for-hematopoietic-stem-cell-transplantation-in-the-east-mediterranean-african-region-comparison-with-global-hsct-indications-and-trends
#16
Helen Baldomero, Mahmoud Aljurf, Syed Z A Zaidi, Shahrukh K Hashmi, Ardeshir Ghavamzadeh, Alaa Elhaddad, Rose-Marie Hamladji, Parvez Ahmed, Lamia Torjemane, Miguel Abboud, Abdelghani Tbakhi, Murtadha Al Khabori, Asma El Quessar, Nosa Bazuaye, Mohamed Amine Bekadja, Salman Adil, Omar Fahmy, Mani Ramzi, Ahmed Ibrahim, Amal Alseraihy, Nour Ben Abdejalil, Mahmoud Sarhan, Mohammed Al Huneini, Lahoucine Mahmal, Hassan ElSolh, Fazal Hussain, Amr Nassar, Hani Al-Hashmi, Amir Ali Hamidieh, Marcelo Pasquini, Yoshihisa Kodera, Nicolaus Kröger, Mohamed Mohty, Gregorio Jaimovich, Juliana Martinez Rolon, Kristjan Paulson, Hildegard Greinix, Daniel Weisdorf, Mary Horowitz, José Nunez, Alois Gratwohl, Jacob Passweg, Mickey Koh, Jeff Szer, Dietger Niederwieser, Nicolas Novitzky
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006...
August 6, 2018: Bone Marrow Transplantation
https://read.qxmd.com/read/30038353/methods-to-prevent-and-treat-relapse-after-hematopoietic-stem-cell-transplantation-with-tyrosine-kinase-inhibitors-immunomodulating-drugs-deacetylase-inhibitors-and-hypomethylating-agents
#17
REVIEW
Yi-Bin Chen, Philip L McCarthy, Theresa Hahn, Sarah A Holstein, Masumi Ueda, Nicolaus Kröger, Michael Bishop, Marcos de Lima
Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount...
July 23, 2018: Bone Marrow Transplantation
https://read.qxmd.com/read/29966760/relative-impact-of-hla-matching-and-non-hla-donor-characteristics-on-outcomes-of-allogeneic-stem-cell-transplantation-for-acute-myeloid-leukemia-and-myelodysplastic-syndrome
#18
Francis Ayuk, Dietrich W Beelen, Martin Bornhäuser, Matthias Stelljes, Tatjana Zabelina, Jürgen Finke, Guido Kobbe, Daniel Wolff, Eva-Maria Wagner, Maximilian Christopeit, Christoph Schmid, Hellmut Ottinger, Christoph Groth, Christoph Faul, Hartmut Bertz, Elena Rachlis, Christine Wolschke, Johannes Schetelig, Peter A Horn, Joannis Mytilineos, Martina Guellstorf, Reinhard Kelsch, Katharina Fleischhauer, Nicolaus Kröger, Wolfgang Bethge
Increasing donor-recipient HLA disparity is associated with negative outcomes of allogeneic hematopoietic stem cell transplantation (HSCT), but its comparative relevance amid non-HLA donor characteristics is not well established. We addressed this question in 3215 HSCTs performed between 2005 and 2013 in Germany for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Donors were HLA-matched related (MRD; n = 872) or unrelated (10/10 MUD, n = 1553) or HLA-mismatched unrelated (<10/10 MMUD, n = 790)...
July 24, 2018: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/29907810/asxl1-ezh2-mutations-promote-clonal-expansion-of-neoplastic-hsc-and-impair-erythropoiesis-in-pmf
#19
Ioanna Triviai, Silke Zeschke, Jan Rentel, Marios Spanakis, Theo Scherer, Razif Gabdoulline, Victoria Panagiota, Felicitas Thol, Michael Heuser, Carol Stocking, Nicolaus Kröger
Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant myeloproliferation from the prime HSC compartment is poorly understood. Genotyping of >2000 colonies from CD133+HSC and progenitors from PMF patients confirmed the complex genetic heterogeneity within the neoplastic population...
June 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://read.qxmd.com/read/29880610/competing-risk-outcomes-after-hematopoietic-stem-cell-transplantation-from-the-perspective-of-time-dependent-effects
#20
Daniel Fuerst, Sandra Frank, Carlheinz Mueller, Dietrich W Beelen, Johannes Schetelig, Dietger Niederwieser, Jürgen Finke, Donald Bunjes, Nicolaus Kröger, Christine Neuchel, Chrysanthi Tsamadou, Hubert Schrezenmeier, Jan Beyersmann, Joannis Mytilineos
The success of hematopoietic stem cell transplantation is determined by multiple factors. Additional complexity is conferred by covariables showing time-dependent effects. We evaluated the effect of predictors on competing-risk outcomes after hematopoietic stem cell transplantation in a time-dependent manner. We analyzed 14951 outcomes of adult patients with hematologic malignancies who underwent a first allogeneic transplant. We extended the combined endpoints of disease-free and overall survival to competing-risk settings: disease-free survival was split into relapse and non-relapse mortality...
September 2018: Haematologica
keyword
keyword
165096
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"